InvestorsHub Logo
Followers 112
Posts 17594
Boards Moderated 0
Alias Born 06/24/2014

Re: None

Wednesday, 09/25/2024 8:06:58 AM

Wednesday, September 25, 2024 8:06:58 AM

Post# of 3335

On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent WINT News